Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoconjugates: lessons from animal models

S Canevari1, M Colombatti, M I Colnaghi

  • 1Experimental Oncology E, Istituto Nazionale Tumori, Milan, Italy.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-PSMA <sup>124</sup>I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle.

Journal of experimental & clinical cancer research : CR·2019
Same author

An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.

Allergy·2018
Same author

Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Safe core-satellite magneto-plasmonic nanostructures for efficient targeting and photothermal treatment of tumor cells.

Nanoscale·2017
Same author

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.

Cell death & disease·2014
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Monoclonal antibody cancer therapy is improving with antibody-drug conjugates. These targeted therapies show promise over traditional unarmed antibodies, advancing cancer treatment strategies.

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Monoclonal antibody therapy has faced challenges in achieving significant therapeutic success.
  • The limitations of unarmed monoclonal antibodies have spurred interest in advanced antibody-based strategies.

Purpose of the Study:

  • To review the evolution of monoclonal antibody-mediated cancer therapy.
  • To discuss the implications of recent studies on antibody-drug conjugates for cancer treatment.

Main Methods:

  • Review of preclinical and clinical studies involving antibody-drug conjugates.
  • Analysis of a specific doxorubicin-anti-carcinoma antibody conjugate report.

Main Results:

  • Interest in antibody-drug conjugates has grown due to the limited efficacy of unarmed monoclonal antibodies.

Related Experiment Videos

  • Numerous studies have explored various antibody-based targeting strategies.

    • Conclusions:

    • Antibody-drug conjugates represent a promising advancement in cancer therapy.
    • Further research and clinical studies are essential to optimize these targeted approaches.